Jennifer Doudna (Photo by Brian Ach/Getty Images for Wired)
June 22, 2022 11:18 AM EDT
Discovery

Doud­na re­search team finds CRISPR-Csm de­liv­ery po­ten­tial­ly out­per­forms RNAi, Cas13

Paul Schloesser

Associate Editor

While RNAi and Cas13 have been used as some of the ear­ly meth­ods for gene si­lenc­ing, a new preprint from top …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times